Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemarituzumab in Squamous-Cell NSCLC
NCT05267470Phase 1Terminated
- Sponsor
- Amgen
- Start
- Mar 2022
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 1, open-label trial of bemarituzumab in squamous cell carcinoma of the lung (LSCC), sponsored by Amgen. Primary endpoints: Number of Participants Who Experienced a Dose Limiting Toxicity and Number of Participants With Treatment-emergent Adverse Events. Started Mar 2022; status: terminated.
02
Drugs
bemarituzumab
03
Conditions
squamous cell carcinoma of the lung (LSCC)
Beyond the preview
Go deeper on NCT05267470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05267470.